Wells Fargo’s Altamira Therapeutics Ltd CYTO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1
| Closed | -$3 | – | 7836 |
|
|
2023
Q4 | $3 | Hold |
1
| – | – | ﹤0.01% | 7536 |
|
|
2023
Q3 | $6 | Hold |
1
| – | – | ﹤0.01% | 7472 |
|
|
2023
Q2 | $16 | Hold |
1
| – | – | ﹤0.01% | 7357 |
|
|
2023
Q1 | $32 | Hold |
1
| – | – | ﹤0.01% | 7239 |
|
|
2022
Q4 | $121 | Hold |
1
| – | – | ﹤0.01% | 6752 |
|
|
2022
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 7687 |
|
|
2022
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 7792 |
|
|
2022
Q1 | $1K | Hold |
1
| – | – | ﹤0.01% | 6905 |
|
|
2021
Q4 | $1K | Sell |
1
-20
| -95% | -$13.4K | ﹤0.01% | 7119 |
|
|
2021
Q3 | $17K | Hold |
21
| – | – | ﹤0.01% | 6032 |
|
|
2021
Q2 | $30K | Buy |
21
+10
| +91% | +$13.7K | ﹤0.01% | 5763 |
|
|
2021
Q1 | $15K | Buy |
11
+1
| +10% | +$1.34K | ﹤0.01% | 6242 |
|
|
2020
Q4 | $10K | Buy |
+10
| New | +$6.44K | ﹤0.01% | 6034 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 6573 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 6504 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 6401 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 6401 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6506 |
|
|
2015
Q4 | – | Hold |
0
| – | -$1K | – | 6482 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 6093 |
|
Other funds holding CYTO
Wells Fargo's CYTO Position: Q1 2024 in Review
Wells Fargo sold out of Altamira Therapeutics Ltd (CYTO) in Q1 2024, closing a stake of 1 share — an estimated $3 sold.
Wells Fargo first reported a position in CYTO in Q4 2020 and held it in 13 quarters. The position peaked at $30K in Q2 2021. 3 funds tracked by Wall St. Rank hold CYTO as of Q1 2024.
- Wells Fargo reported no remaining Altamira Therapeutics Ltd position as of Q1 2024 after selling out during the quarter.
- Wells Fargo sold 1 Altamira Therapeutics Ltd share in Q1 2024, an estimated $3.
- Wells Fargo first reported a position in Altamira Therapeutics Ltd in Q4 2020 and held it in 13 quarters.
- Wells Fargo's Altamira Therapeutics Ltd position peaked at $30K in Q2 2021.
- 3 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q1 2024.
Based on Wells Fargo's 13F filing for Q1 2024, filed 10 May 2024.